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Abstract
Background
Calcium electroporation is a new experimental anti-cancer treatment where calcium is inter-
nalized into cells by application of short, high voltage pulses. Calcium electroporation has
been shown to induce tumor necrosis associated with ATP depletion while the effect on nor-
mal fibroblasts was limited when investigated in a 3D in vitro spheroid model. We aimed to
investigate the effect of calcium electroporation in combination with metformin, a drug that
affects intracellular ATP level. We also aimed to study the relationship between the viability
and intracellular ATP levels after calcium electroporation in vitro.
Methods
In this study, we investigated the effect of calcium electroporation with metformin on NMRI-
Foxn1nu mice in vivo on tumor size, survival, and intracellular ATP. We further investigated
viability and intracellular ATP level in vitro after calcium electroporation in two human
cancer cell lines: Breast (MDA-MB231) and colon (HT29), and in normal human fibroblasts
(HDF-n), as well as investigating viability in human bladder cancer cells (SW780) and
human small cell lung cancer cells (H69) where we have previously published intracellular
ATP levels.
Results
Calcium electroporation significantly reduced the size and ATP level of bladder cancer
tumors treated in vivo but no increased effect of metformin combined with calcium electropo-
ration was shown on neither tumor size, survival, nor ATP level. Calcium electroporation in
vitro significantly decreased viability compared with calcium alone (p<0.0001 for calcium
concentrations from 0.5 mM for H69, HDF-n, and MDA-MB231; p<0.0001 for calcium con-
centrations from 1 mM for HT29 and SW780). Intracellular ATP levels decreased signifi-
cantly after calcium electroporation (p<0.05), however no correlation between intracellular
ATP level and viability after treatment was observed.
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Conclusion
Calcium electroporation caused reduced tumor size, increased survival, and acute ATP
depletion in vivo. This effect was not augmented by metformin. Calcium electroporation is a
possible novel anti-cancer treatment that has been shown to cause cell death associated
with acute ATP depletion in vitro and in vivo.
Introduction
Electroporation is a method where application of short, high voltage pulses causes transient
permeabilization of the cell membrane, letting ions and molecules enter and leave the cell
[1–3]. Electroporation based treatments include electrochemotherapy, where chemotherapeu-
tic agents are internalized into tumor cells, because permeabilization of the membrane by elec-
troporation allows direct access to the cell cytosol [4–9]. Electrochemotherapy is in clinical use
for cutaneous tumors [10–16], and in development or clinical trials for tumors situated in e.g.
bone [17], pancreas [18], brain [17], the colon/rectum [19], as well as head- and neck cancers
[20]. Irreversible electroporation [21–23] is also used clinically, and with this technology per-
meabilization of the cell membrane is much more pronounced, so that tumor cells are exten-
sively permeabilized, leading to cell death associated with loss of ionic homeostasis, and energy
depletion. Finally, nanosecond pulses have been shown to induce cell death [24, 25] by per-
meabilizing internal organelles such as the mitochondria, and this technology is also entering
clinical trials.
A novel use of electroporation is calcium electroporation, where high calcium concentra-
tions are introduced into the cell cytosol, and this has been proposed as a potential novel anti-
cancer treatment [26]. Calcium is an important ubiquitous second messenger involved in
numerous cellular processes [27–30], and can be involved in development of the malignant
phenotype [31, 32]. Calcium electroporation has been studied in vitro [26, 33, 34], in 3D spher-
oids [35], and has previously been shown to induce tumor necrosis in vivo [26], and a clinical
trial treating cutaneous metastases is ongoing (ClinicalTrials.gov ID- NCT01941901). Calcium
electroporation has also been shown to be associated with acute ATP depletion [26, 35, 36].
Thus, it could be assumed that combination of calcium electroporation with another treatment
affecting the cell metabolism and thereby the intracellular ATP level might have an additive
effect. Such a treatment could be metformin, a biguanide that reduces blood glucose, and is a
commonly used drug for treatment of type 2 diabetes. Metformin exerts a number of effects
including reducing the ATP production by binding to and inhibiting complex I of the mito-
chondrial respiratory chain [37]. Thus, the mitochondrial ATP production is inhibited by met-
formin causing a reduced intracellular ATP level, leading to changed ATP/AMP ratio which
activates AMP-activated protein kinase (AMPK). This activation causes inhibition of cell sur-
vival, growth, and proliferation; thus, contributing to an anti-cancer effect [37–40].
We hypothesized that the ATP reducing effect of metformin and calcium electroporation
could be additive. The aim of this study was therefore to test the effect on viability, tumor size,
and ATP levels in tumors, after treatment with systemic metformin in combination with local
treatment with calcium electroporation on a nude mouse model. We also aimed to determine
the relationship between viability and ATP depletion after calcium electroporation, in a num-
ber of different cell lines in vitro in order to investigate possible differences in sensitivity and
effect.
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Methods
Cell culture
Four different human cancer cell lines were used: MDA-MB231, breast adenocarcinoma
(ATCC #HTB-26), SW780, bladder transitional cell carcinoma (kindly provided by Dr. Lars
Dyrskjøt Andersen, Department of Molecular Medicine, Aarhus University Hospital, Skejby,
Denmark) [41], H69, small cell lung carcinoma (kindly provided by the Department of Radia-
tion Biology, Copenhagen University Hospital, Denmark) [42], and HT29, colorectal adeno-
carcinoma (ATCC #HTB-38). HDF-n, a primary normal human dermal fibroblast cell line
(kindly provided by Dr. Marie-Pierre Rols, Institute of Pharmacology and Structural Biology,
IPBS, Toulouse, France) [35] was also used in this study. MDA-MB231, SW780, and HDF-n
were grown in DMEM, and H69 and HT29 were grown in RPMI-1640 culture medium
(Gibco, Invitrogen) with 10% fetal calf serum (Gibco, Invitrogen), 100 U/ml penicillin, and
100 μg/ml streptomycin and kept at 37˚C and 5% CO2.
Cells were tested negative for mycoplasma using MycoAlert mycoplasma detection kit
(Lonza). Cancer cell lines were tested negative for infection using rapid MAP27 panel
(Taconic), and authenticated by short tandem repeat (STR) profiling (LGC Standards)
showing perfect match for SW780, H69, and HT29. The MDA-MB231 cell line matched in 7
of 9 profile loci (loci D7 and VWA have lost a peak) assessed not to influence the results of this
study.
Tumor studies in vivo
In vivo experiments were conducted in accordance with European Convention for the Protec-
tion of Vertebrate Animals used for Experimentation and with permission from the Danish
Animal Experiments Inspectorate (# 2012-15-2934-00091).
Experiments were performed as described previously [26]. Briefly, 5.0 x 106 cells in 100 μl
PBS were injected subcutaneously in the flank of NMRI-Foxn1nu mice (9–19 weeks old,
males and females, 25–44 g (median 33 g) at treatment time, bred at Department of
Oncology, Herlev Hospital, Denmark). Tumor volume was calculated as axb2xπ/6, where a is
the longest diameter and b is the longest diameter perpendicular to a. At a tumor volume
above 85 mm3, mice were randomized into the different groups according to a predefined
randomization scheme. Thus, animals were randomized into the different treatment groups
immediately before treatment securing similar weight and health status in all treatment
groups.
Animals were housed in 425x266x150 mm cages with polyester filter sheet top (Scanbur)
with environmental enrichment in groups of up to 8 mice with access to rat/mouse food
(Altromin #1314, Brogaarden) and water ad libitum. The environmental conditions were a
temperature of 22.3˚C (SD 0.6˚C), humidity of 48% (SD 7%), and a 12:12 dark:light cycle.
Before treatment, mice were anesthetized (also untreated controls) by intraperitoneal injection
of hypnorm and midazolam, and treatment was performed during the day in a laboratory in
the animal facility. Tumors treated with electroporation were applied to 8 pulses of 1.0 kV/cm
(applied voltage to electrode distance ratio), 100 μs, and 1 Hz using a 6 mm plate electrode and
a square wave electroporator (Cliniporator, IGEA). Contact between electrode and tumor was
ensured by ultrasound gel.
Humane endpoints were used to determine end of the experiments (i.e. tumors larger than
905 mm3, body weight decrease larger than 20% from pre-treatment, or sickness), where mice
were euthanized by cervical dislocation. Mice were monitored daily for discomfort and sick-
ness, three times a week for tumor size, and once a week for body weight.
Effect of calcium electroporation in combination with metformin in vivo
PLOS ONE | https://doi.org/10.1371/journal.pone.0181839 July 25, 2017 3 / 12
Effect on tumor volume of treatment combined with metformin
The SW780 cell line was used for this experiment since this cell line has been shown to be least
sensitive to calcium electroporation of the four cancer cell lines when treated in vivo [43]. It
has previously been shown that SW780 cells are sensitive to metformin [44]. Mice were ran-
domized into 8 groups treated with (i) 168 mM CaCl2 injection with or without electropora-
tion or (ii) physiological saline injection with or without electroporation; all treated either with
or without metformin. Tumors were injected with CaCl2 or physiological saline volumes
equivalent to half the tumor volume.
Before treatment (3–4 hours) mice were injected intraperitoneally (ip) with metformin
(250 mg/kg) or PBS (10 ml/kg). Metformin groups were given metformin in the drinking
water (2 mg/ml) for 2 weeks after treatment to sustain the expected effect of metformin on the
ATP level in the tumors. The drug was active since we observed side effects on the mice as
described in the Results and Discussion section. Before treatment and three times a week after
treatment, tumor volume was measured using a Vernier caliper.
Effect on intracellular ATP level of treatment combined with metformin
All four cancer cell lines were used for this experiment. Mice were injected with 5.0 x 106 cells
in 100 μl PBS as described above, except for the SW780 cells where 4.8 x 106 cells in 100μl PBS
were injected. Mice were randomized into the same 8 groups as described above, and injected
ip 3–4 hours before treatment with metformin (250 mg/kg) or PBS (10 ml/kg). Around 1 hour
after treatment with CaCl2 or NaCl with or without electroporation tumors were removed,
halved, and put in 1 ml ice cold 5% TCA overnight. Tumors were lysed at 30 Hz for 4–10 min
using a Tissue Lyser (Qiagen), centrifuged at 500 g for 2 min, and supernatant was diluted
7500 times in Tris-Acetate-EDTA (TAE). ATP content was determined using ELITEN ATP
assay (Promega) and light emission was measured using LUMIstar (Ramcon).
Viability in vitro
After harvesting, cells were washed and diluted to 6.1x106 cell/ml in HEPES buffer (10mM
HEPES (Lonza), 250 mM sucrose, and 1 mM MgCl2 in sterile water), and cooled on ice. The
4 mm aluminum electrode cuvettes (Molecular BioProducts, Inc.) placed in a cooling block,
and 30 μl CaCl2 (final concentration of 0.25–5.0 mM) or HEPES buffer for controls were
added to the cuvettes followed by addition of 270 μl cells. Cells incubated in the cuvettes for
5 min before electroporation or not. Cells were exposed to 8 pulses of 99 μs, 1 Hz, and
1.2 kV/cm (applied voltage to electrode distance ratio) using a square wave electroporator
(BTX T820). After this, the cells incubated in the cuvettes at 37˚C and 5% CO2 for 20 min,
before they were transferred to culture medium and seeded in 96-well plates (3.1x104 cells per
100 μl). MTS assay was performed 1 day after treatment using Multiskan-Ascent ELISA reader
(Thermo Labsystems).
ATP assay in vitro
Cells were treated as described above with 0, 1, 3, and 5 mM calcium with or without electro-
poration. Cells were seeded in white 96-well plates as described above and lysed 1, 2, 4, and
8 hours after treatment before ATP content was determined using ENLITEN ATP assay (Pro-
mega) and LUMIstar luminometer (Ramcon).
Statistics
Statistical analyses were performed using SAS software (version 9.2).
Effect of calcium electroporation in combination with metformin in vivo
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Differences in cell viability in vitro and differences in intracellular ATP level in vitro and in
vivo were assessed by 2-way analysis of variance (ANOVA) with post least-squares-means test
with Bonferroni correction. ATP level in HT29 and MDA-MB231 tumors were log trans-
formed before analysis.
Difference in survival after treatment was assessed using a Log-Rank test with death due to
tumor size (above 905 mm3) defined as event and death due to disease was censored.
SPSS software (version 19) was used to evaluate difference in tumor volume after treatment
with linear mixed model.
Results and discussion
Calcium electroporation combined with metformin treatment—Effect on
tumor volume
To investigate if a systemic metformin treatment, which affects cell metabolism by inhibiting
the mitochondrial ATP production [37], could increase the effect of the local treatment with
calcium electroporation we tested this combination on SW780 (bladder cancer) tumors in
nude mice (Fig 1b). The lowest tumor volume was seen in mice treated with calcium electropo-
ration and metformin, however not significantly lower than in mice treated with calcium elec-
troporation (p = 0.056; Fig 1b). Mice treated with calcium electroporation had significantly
lower tumor volume than mice treated with calcium alone (p<0.05), similar to previous find-
ings in a different tumor model [26]. This shows that calcium electroporation is effective in
different tumor types. Looking at survival after treatment (Fig 1a), no significant difference in
survival was seen between calcium electroporation with or without metformin treatment. For
further analyses, the results for all mice were pooled into two groups treated with or without
metformin (Fig 1c and 1d) showing no difference between the two groups in the effect after
treatment on neither tumor volume nor survival. When pooling the data into two groups
treated with or without electroporation, a significantly lower tumor volume (p<0.0001) and
longer survival (p<0.001) was shown for mice in the electroporation group (Fig 1e and 1f),
demonstrating that electroporation, as expected, increases the effect of the drugs.
The calcium concentration used in vivo was 168 mM, much higher than the concentrations
causing cell death in vitro (>0.5–1.0 mM depending on the cell line used), due to the very
small extracellular space in tumors compared with in vitro, as well as expected dilution to the
remaining extracellular volume of the animal.
Effect on intracellular ATP level after calcium electroporation combined
with metformin treatment
The intracellular ATP level in tumors was measured 1 hour after treatment to investigate if
calcium electroporation in vivo induced ATP depletion like in vitro, and to test if the
additional metformin treatment further decreased the ATP level (Fig 2). We measured the
ATP level in four different tumors (small cell lung cancer, colon cancer, breast cancer, and
bladder cancer) treated with calcium electroporation with or without additional metformin
treatment.
The results showed that addition of metformin did not significantly decrease the ATP level.
Since neither tumor size, survival, nor ATP level was significantly affected by addition of met-
formin injection this might be due to the chosen concentrations used, and it could be hypothe-
sized that changing the concentration of metformin could have an effect. An effect might have
been shown by increasing the concentration but 20 out of 89 mice treated with metformin had
a slightly lowered body temperature 3 hours after injection, and were put in a cage on a
Effect of calcium electroporation in combination with metformin in vivo
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Fig 1. Effect of calcium electroporation and metformin treatment. SW780 (human bladder cancer) tumors treated with 168mM calcium or
physiological saline with or without electroporation (EP) and with or without metformin treatment. Kaplan Meier curves after treatment shown for all
treatment groups (a), and for pooled data for groups treated with (black) or without (green) metformin (c), as well as for groups treated with (red) or
without (blue) electroporation (e). Death due to tumor size (above 905mm3) was defined as event and death due to disease was censored. Tumor
volume in days after treatment shown for each treatment group (b), and for pooled data for groups treated with (black) or without (green) metformin
(d), as well as for groups treated with (red) or without (blue) electroporation (f). The original treatment groups treated with (gray) or without (light green)
metformin (c-d), as well as for groups treated with (light red) or without (light blue) electroporation (e-f) is shown in faded colors in the background.
Mean + SD, n > 7 is shown in the graph. n = 9–11 before treatment.
https://doi.org/10.1371/journal.pone.0181839.g001
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warming block. This indicate that the used concentration was toxic and too high, thus, we did
not try with a higher concentration of metformin due to the observed adverse effects.
In control tumors treated only with physiological saline the ATP level was between
0.21–0.29 nmol/mg tumor. When treating tumors with calcium electroporation, the ATP level
was significantly lower than in controls (p<0.05 in all tumor types), as seen in vitro (Fig 3 and
S1 Fig). Treatment with physiological saline and electroporation significantly reduced intracel-
lular ATP level only in the small cell lung cancer tumors (p<0.01). In vitro, it was also shown
that electroporation alone significantly decreased the ATP level 1 hour after treatment in H69
(small cell lung cancer), MDA-MB231 (breast cancer) cells, and HDF-n (normal fibroblasts)
(p<0.0001). This decrease after electroporation alone is likely due to direct loss of ATP
through the permeabilized membrane and re-establishment of ionic homeostasis using ATP
dependent pumps. In some of the cell lines and tumors, no significant decrease in ATP level
after electroporation alone was observed, which could be due to no or lower direct loss of
ATP, or due to re-establishment of the ATP level within 1 hour after treatment.
It has previously been shown that electroporation cause a vascular effect in tumors, where
the blood flow in the treated area is reduced around 60% for up to 2 hours after treatment
[45, 46]. This reduced blood flow likely causes limited access of nutrients needed for the cells
to produce ATP, thereby increasing the effect of calcium electroporation. This effect might
have been seen if the tumors were removed at a later time after treatment.
Viability in vitro after calcium electroporation
Viability in different cancer cell lines and a primary normal cell line after treatment with
increasing calcium concentration with or without electroporation is depicted in Fig 3 and in
S1 Fig. As previously shown [26, 36], treatment with calcium alone did not affect viability
whereas calcium electroporation induced dramatic decrease in viability (p<0.0001 for concen-
trations above 0.5 mM for H69, HDF-n, and MDA-MB231; p<0.0001 for concentrations
above 1 mM for HT29 and SW780) with concentrations causing 50% cell death ranging from
0.37–1.25 mM CaCl2 in the five cell lines (Table 1). Viability of normal primary fibroblasts
decreased (50% cell death at 0.48 mM) after calcium electroporation, like viability of the cancer
cells. However, it has been shown that normal primary fibroblasts were much less affected
than cancer cell lines after calcium electroporation, when treated as spheroids (a multicellular
Fig 2. Intracellular ATP in tumors after treatment with calcium electroporation and metformin treatment. Four different human tumor
types; H69, a small cell lung cancer, HT29, a colon cancer, MDA-MB231, a breast cancer, and SW780, a bladder cancer treated with 168mM
calcium or physiological saline with or without electroporation (EP). Metformin or PBS was injected ip 3–4 hours before treatment, tumors were
removed around 1 hour after treatment, and ATP level was measured after lysis overnight. Mean + SD, n = 5–7 (H69), n = 6–8 (HT29), n = 4–5
(MDA-MB231), n = 4–6 (SW780).
https://doi.org/10.1371/journal.pone.0181839.g002
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3D in vitro model) [35]. This might be due to the model systems used, where cells in a spheroid
are densely packed and forming intercellular junction and anatomical communication [47],
unlike cells in suspension that are separate from each other, are not oriented, and have a very
large extracellular volume. Cells in spheroids better mimic cells in tissue and it has recently
been shown that normal tissue is less affected that tumor tissue to calcium electroporation
[43].
Electroporation alone also affected the cells where viability decreased the most in H69 cells
(27% decrease in viability after electroporation, p<0.0001), followed by SW780 (19%,
Fig 3. Viability and intracellular ATP level after calcium electroporation in vitro. Two human cancer cell lines (HT29, colon cancer and
MDA-MB231, breast cancer) and a normal primary human dermal fibroblast cell line (HDF-n) were treated with increasing concentration of
calcium with or without electroporation (EP). Viability was measured 1 day after treatment and intracellular ATP level was measured 1, 2, 4,
and 8 hours after treatment. Mean +/- SD, n = 4–9.
https://doi.org/10.1371/journal.pone.0181839.g003
Table 1. Sensitivity to calcium electroporation in vitro measured by 50% cell death.
Calcium concentration causing 50% cell death
Cell line mM
MDA-MB231 0.37
HDF-n 0.48
H69 0.56
SW780 0.80
HT29 1.25
Calcium concentration, where 50% of cells were dead, was estimated from graphs in Fig 3 and S1 Fig.
Viability of untreated control was denoted as 100%.
https://doi.org/10.1371/journal.pone.0181839.t001
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p = 0.0797), MDA-MB231 (16%, p = 0.1191), HT29 (12%, p = 1), and the normal cell line
HDF-n, where viability only decreased 2% after electroporation (p = 1).
Intracellular ATP level in vitro after calcium electroporation
To investigate if viability of cells after calcium electroporation is related to the intracellular cal-
cium concentration before or after treatment, the intracellular ATP level was determined 1, 2,
4, and 8 hours after treatment with increasing CaCl2 concentration (0–5 mM) with or without
electroporation. The ATP level decreased significantly after calcium electroporation compared
with treatment without electroporation (p<0.0001; Fig 3), as previously shown (S1 Fig)
[26, 36]. It has also previously been shown that the ATP level decreases after electroporation
alone [26, 36], which is also shown here, where the ATP level decreased 1 hour after treatment
with electroporation alone in HDF-n, and MDA-MB231 cells (p<0.0001). This is likely due
to direct loss of ATP through the permeabilized cell membrane as well as ATP used to re-
establish ion homeostasis after permeabilization by employing ATP dependent membrane
pumps; however, the cells re-established the ATP level over time where no significant differ-
ence was seen 8 hours after treatment.
Increasing calcium concentrations were used in this experiment, and the ATP level was sig-
nificantly lower when electroporating with 5 mM calcium than when electroporating with 1
mM calcium in all cell lines 2, 4, and 8 hours after treatment (p<0.05), except in the H69 cell
line (p = 1.000) as previously shown (S1 Fig), indicating a dose response on the ATP depletion
caused by calcium electroporation. The ATP level was very low in the H69 cell line after treat-
ment with 1 mM calcium electroporation, and this is probably the reason why no further
decrease in ATP level was seen in this cell line.
The intracellular ATP depletion after calcium electroporation in relation to the viability of
the cells after treatment was investigated. In untreated cells, the intracellular ATP level varied
between the cell lines; H69 (previously published) had the lowest intracellular ATP concentra-
tion of 0.26 nmol ATP per million cells followed by HT29 (0.65 nmol ATP/mio cells),
MDA-MB231 (1.31 nmol ATP/mio cells), SW780 (1.50 nmol ATP/mio cells; previously pub-
lished), and HDF-n with the highest intracellular ATP concentration of the tested cell lines
(1.52 nmol ATP/mio cells). The intracellular ATP level in cells before treatment might affect
their ability to survive treatment with calcium electroporation, since the treatment is associ-
ated with ATP depletion. However, there is no correlation between intracellular ATP level in
untreated cells and sensitivity to treatment in vitro, measured in calcium concentrations caus-
ing 50% cell death in combination with electroporation (Table 1). An important point might
be that not only the ATP depletion affects viability, but also the cells sensitivity to this
depletion.
Conclusion
This study showed that systemic metformin treatment did not increase the effect of calcium
electroporation in vivo, neither on tumor size, survival, nor ATP level in the model tested. We
also showed that calcium electroporation was associated with significant ATP depletion both
in vitro and in vivo, and consistently in four different malignant cell lines. However, we did not
see a relation between ATP level in cells before treatment and sensitivity to the treatment. We
have previously shown that calcium electroporation induces tumor necrosis, and was pre-
sented as a possible novel anti-cancer treatment. In this study, we have not shown increased
effect when combining the treatment with metformin but further research to understand the
mechanism behind calcium electroporation could lead to optimization of this promising novel
anti-cancer treatment.
Effect of calcium electroporation in combination with metformin in vivo
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Supporting information
S1 Fig. Viability and intracellular ATP level after calcium electroporation in vitro. Two
human cancer cell lines (H69, small cell lung cancer and SW780, bladder cancer) were treated
with increasing concentration of calcium with or without electroporation (EP). Viability was
measured 1 day after treatment and intracellular ATP level was measured 1, 2, 4, and 8 hours
after treatment. Mean +/- SD, n = 4–9. The ATP data has previously been published but illus-
trated differently [36]. The data is also presented in this study to compare ATP level in five cell
lines (Fig 3) as well as to compare the ATP levels with viability in each cell line.
(TIF)
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